Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hypertrophic Cardiomyopathy - Pipeline Review, H1 2016', provides an overview of the Hypertrophic Cardiomyopathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy
- The report reviews pipeline therapeutics for Hypertrophic Cardiomyopathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hypertrophic Cardiomyopathy therapeutics and enlists all their major and minor projects
- The report assesses Hypertrophic Cardiomyopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hypertrophic Cardiomyopathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hypertrophic Cardiomyopathy Overview 6
Therapeutics Development 7
Pipeline Products for Hypertrophic Cardiomyopathy - Overview 7
Pipeline Products for Hypertrophic Cardiomyopathy - Comparative Analysis 8
Hypertrophic Cardiomyopathy - Therapeutics under Development by Companies 9
Hypertrophic Cardiomyopathy - Therapeutics under Investigation by Universities/Institutes 10
Hypertrophic Cardiomyopathy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Hypertrophic Cardiomyopathy - Products under Development by Companies 13
Hypertrophic Cardiomyopathy - Products under Investigation by Universities/Institutes 14
Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development 15
Gilead Sciences, Inc. 15
Heart Metabolics Limited 16
miRagen Therapeutics, Inc. 17
MyoKardia, Inc. 18
Hypertrophic Cardiomyopathy - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
eleclazine - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
HCM-2 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MGN-9103 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MYK-461 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
perhexiline maleate - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ranolazine ER - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule for Cardiac Hypertrophy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Hypertrophic Cardiomyopathy - Recent Pipeline Updates 38
Hypertrophic Cardiomyopathy - Dormant Projects 42
Hypertrophic Cardiomyopathy - Discontinued Products 43
Hypertrophic Cardiomyopathy - Product Development Milestones 44
Featured News & Press Releases 44
May 02, 2016: MyoKardia Receives Orphan Drug Designation for MYK-461 for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy 44
Mar 15, 2016: Heart Metabolics Announces Multiple Senior Appointments to Management Team 44
Feb 04, 2016: MyoKardia Publishes Article in Science Demonstrating That MYK-461 Prevents and Reverses Disease in Genetic Mouse Models of Hypertrophic Cardiomyopathy 45
Oct 06, 2015: MyoKardia Provides Update on Two Phase 1 Trials of MYK-461 for the Treatment of Hypertrophic Cardiomyopathy 46
Apr 15, 2015: Heart Metabolics and FDA Reach Agreement on Special Protocol Assessment for Single Phase 3 Trial of Perhexiline in Hypertrophic Cardiomyopathy 46
Mar 03, 2015: MyoKardia Announces Initiation of Phase 1 Clinical Study of MYK-461 for Hypertrophic Cardiomyopathy 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for Hypertrophic Cardiomyopathy, H1 2016 7
Number of Products under Development for Hypertrophic Cardiomyopathy - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Hypertrophic Cardiomyopathy - Pipeline by Gilead Sciences, Inc., H1 2016 15
Hypertrophic Cardiomyopathy - Pipeline by Heart Metabolics Limited, H1 2016 16
Hypertrophic Cardiomyopathy - Pipeline by miRagen Therapeutics, Inc., H1 2016 17
Hypertrophic Cardiomyopathy - Pipeline by MyoKardia, Inc., H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Hypertrophic Cardiomyopathy Therapeutics - Recent Pipeline Updates, H1 2016 38
Hypertrophic Cardiomyopathy - Dormant Projects, H1 2016 42
Hypertrophic Cardiomyopathy - Discontinued Products, H1 2016 43